Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.0%
    Check dated 2026-10-31T14:33:34.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    0.3%
    Check dated 2026-10-24T13:50:53.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2; the clinical trial record history remains unchanged.
    Difference
    0.0%
    Check dated 2026-10-17T14:38:35.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays site revision v3.7.1 instead of v3.7.0.
    Difference
    0.0%
    Check dated 2026-10-10T15:39:09.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The UI text changed from 'Find Contact Information' to 'Find contact information' to adjust capitalization, and the footer revision label updated from v3.6.6 to v3.7.0.
    Difference
    0.1%
    Check dated 2026-09-19T18:53:30.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    A new revision entry, v3.6.6, was added to the study record history, and the previous revision, v3.6.5, was removed from the current listing.
    Difference
    0.0%
    Check dated 2026-08-29T20:19:32.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.